News
$BioAtla (BCAB.US)$ Reuters· just
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Bioatla Granted FDA Fast Track Designation for Ozuriftamab Vedotin (Cab-Ror2-ADC) for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
